Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue				$ 900,000
Operating expenses:
Research and development (net of collaboration funding of $2,178,078 and $3,454,881 in the three months ended September 30, 2022 and 2021, respectively, and of $6,826,080 and $4,766,919 in the nine months ended September 30, 2022 and 2021, respectively)	$ 2,681,680	$ 1,435,461	$ 9,280,092	4,802,653
General and administrative (net of collaboration funding of $1,432,889 and $958,590 in the three months ended September 30, 2022 and 2021, respectively, and of $7,062,766 and $1,561,124 in the nine months ended September 30, 2022 and 2021, respectively)	2,557,370	1,843,360	10,071,044	7,626,009
Total operating expenses	5,239,050	3,278,821	19,351,136	12,428,662
Loss from operations	(5,239,050)	(3,278,821)	(19,351,136)	(11,528,662)
Other income (expense), net:
Costs of debt issuance	(122,400)		(1,490,594)
Changes in fair value of debt instruments	324,550		4,091,610
Interest and other income (expense), net	19,431	(2,471)	(122,641)	522,280
Foreign currency transaction gain	10,524	8,284	19,776	53,032
Total other income (expense), net	232,105	5,813	2,498,151	575,312
Net loss	$ (5,006,945)	$ (3,273,008)	$ (16,852,985)	$ (10,953,350)
Net loss per share - basic	$ (0.31)	$ (0.23)	$ (1.11)	$ (0.77)
Weighted average common shares outstanding - basic	16,089,019	14,310,244	15,230,839	14,254,092
Net loss per share - diluted	$ (0.31)	$ (0.23)	$ (1.13)	$ (0.77)
Weighted average common shares outstanding - diluted	16,089,019	14,310,244	17,085,784	14,254,092